Dr. Steffen Hennig, CEO:  SH is co-founder and CEO of HSDiagnomics since 2012. He holds a PhD in Theoretical Physics from University of Goettingen, but switched into the field of Molecular Genomics and Bioinformatics in 1995, where he joined the group of Hans Lehrach at the MPIMG in Berlin, Dahlem. He has extensive experience in genomics and bioinformatics, with a special focus on sequence analysis. In 2007, he was co-founder of imaGenes GmbH, where he was heading the bioinformatics and the service groups. From 2010-2012 he was head of Bioinformatics at Source Bioscience, Nottingham. Apart from his CEO position at HSDiagnomics SH is directing the bioinformatics developments and applications. He is inventor of the TCRsafe system, together with VS and other colleagues.  

 

Martin Stock; CFO: MS is a co-Founder of HSD. He holds a MBA and worked for many years in the fields of Controlling and Finance for several companies, before joining the RZPD, German Ressource Center for Genome Research GmbH in 2011 as administrative director. In 2007, he was co-founder of imaGenes GmbH, which took over the operations from the RZPD through a Management-Buyout. From 2010 – 2014 he was General Director Germany at Source Bioscience, Nottingham. MS is a CFO with broad experience in Finance, Accounting, Legal, HR and Quality-Management in BioTech companies.

 

Dr. Volkhard Seitz, CSO:  VS holds a doctoral degree in biochemistry. His scientific focus are molecular alterations in malignant lymphomas and the understanding of the complex mechanisms of T- and B-cell rearrangements. Currently, he is a senior scientist at the Charité in the Institute of Pathology (Experimental Hematopathology; Prof. Michael Hummel) and co-founder of HSDiagnomics. VS was winner of the Berlin-Brandenburg business competition and is a member of the German National Academic foundation. His personal mission is to translate research into practical clinical applications and to support the fight against lymphomas and other haematological diseases. VS is an important driver for the technologies developed by HSDiagnomics and co-inventor of the TCRsafe system.

 

Dr. Ing. Anja Dröge:  AD studied Biotechnology at the TU Berlin and performed her PhD at the the Max Planck Institute for Molecular Genetis, Berlin (1994-1998). From 2000-2007 she worked as a post doctoral fellow on the pathogenesis of neurodegenerative diseases (Huntington’s Disease, Spinocerebellar Ataxias) in the group of Prof. Wanker at the Max Delbrück Center for Molecular Medicine. AD is co-founder of SINA Science Services GmbH, a company offering service and support on advanced molecular biology projects. In 10/2013 she joined the team of HSDiagnomics as co-partner and R&D manager. AD is a senior scientist and expert in a broad range of molecular biological technologies.

 

Dr. Sigrid Schaper:  SS studied Biochemistry at the Freie Universität Berlin and performed her PhD thesis at the Max Planck Institute for Molecular Genetis, Berlin (1992-1995). From 1998 – 2001 she was a fellow of the Human Frontier Science Programme Organization in the group of Prof. Yaniv at the Institut Pasteur, Paris. In 2001 she moved back to the Max Planck Institute for Molecular Genetics where she conducted research on chromatin remodeling. In 2007, she was co-founder of SINA Science Services GmbH, a company specialized in advanced molecular biology services, together with AD. SS is a senior scientist and expert in biochemical and molecular biological technologies. Since 10/2013 she is co-partner and R&D manager at HSDiagnomics.

 

Prof. Dr. Rudolf Hammer:   RH studied biology and pharmacology in Austria, U.S. and Germany, and was a senior manager at Boehringer Ingelheim (BI) until 2008 in several leading positions, e.g. from 1992-2000 he was head of research at BI Germany with responsibilities for up to 500 researchers.  Being a researcher at BI in the 1970s he discovered the subtypes of the muscarinic acetylcholine receptors which was the starting point for the pharmacology and therapy of subtype selective muscarinic ligands. As a member of HSDiagnomics RH supports the company scientifically and strategically in the development of new technologies and their commercialization.

 

Dr. Jörn Glökler: JG studied biology with a focus on genetics and biochemistry at the University of Bayreuth. In his doctoral thesis he employed phage display technology to find new peptide ligands to metal chelates suitable for affinity chromatography of recombinant fusion proteins. He has worked as a group leader at the Max-Planck Institute for Molecular Genetics in Berlin (2008-2011) to establish novel protocols in high-throughput screening technologies such as protein microarrays, SELEX, DNA encoded libraries in conjunction with next-generation sequencing and biosensors. He has gained profound experience in applied scientific research working for biotech companies and IP law firms. As an inventor he has filed several patent applications including coupled sequencing and sorting of immune cells. Within HSD, JG is a senior advisor for these technologies and IP-related strategies.

 

 

 

Advisors to HSDiagnomics

 

Dr. Volker Lennerz:  VL is advisor to HSD from 10/2016 on. He is a senior scientist in the group of Prof. Wölfel at the University Clinics Mainz (Medizinische Klinik III) and has published pioneering studies about techniques for unraveling tumor associated neo-antigens in melanoma. Using different technology platforms, e.g. cDNA expression cloning as well as Next Generation Sequencing, he contributed to the identification and molecular characterization of numerous tumor antigens in a variety of patient models. VL will give important impact to HSDs novel developments in the field of tumor neo-antigen identification in NSCLC and other cancer types.

 

Dr. Hans-Jörg Warnatz:  HJW is project leader at the MPI for Molecular Genetics in Berlin, where he is investigating adaptive immune receptor repertoires from B- and T-cells including paired immunoglobulin heavy and light chain repertoires. His current areas of research are vaccine efficacy studies, monitoring of autoimmune disorders and Treg-based cell therapies for chronic graft-versus-host disease. Within HSDiagnomics, HJW is an advisor to HSD for paired sequencing technologies and sorting of immune cells.

 

Prof. Dr. Armin Gerbitz:  AG is professor for “Hematology and Cellular Therapy” at the Dep. of Medicine 5, Hematology/Oncology, Hematopoietic Stem Cell Transplantation, University Hospital of Erlangen. For more than 15 years his main research focus lies in allogeneic hematopoietic stem cell transplantation, diagnostics and therapies of malignant lymphoms and leukemia, and therapy related problems like Graft-versus-Host-Disease (GvHD) and reactivation of latent herpes viruses. He is an expert in human and murine immune cell biology and has long-standing expertise in murine model systems. Within HSDiagnomis AG is a senior advisor for all aspects of T-cell profiling, related technologies and upcoming applications in T-cell based treatments and diagnostics, e.g. novel tumor therapies.